Literature DB >> 12593652

Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.

Eva M Krovat1, Thierry Langer.   

Abstract

Chemical feature based pharmacophore models were elaborated for angiotensin II receptor subtype 1 (AT(1)) antagonists using both a quantitative and a qualitative approach (Catalyst HypoGen and HipHop algorithms, respectively). The training sets for quantitative model generation consisted of 25 selective AT(1) antagonists exhibiting IC(50) values ranging from 1.3 nM to 150 microM. Additionally, a qualitative pharmacophore hypothesis was derived from multiconformational structure models of the two highly active AT(1) antagonists 4u (IC(50) = 0.2 nM) and 3k (IC(50) = 0.7 nM). In the case of the quantitative model, the best pharmacophore hypothesis consisted of a five-features model (Hypo1: seven points, one hydrophobic aromatic, one hydrophobic aliphatic, a hydrogen bond acceptor, a negative ionizable function, and an aromatic plane function). The best qualitative model consisted of seven features (Hypo2: 11 points, two aromatic rings, two hydrogen bond acceptors, a negative ionizable function, and two hydrophobic functions). The obtained pharmacophore models were validated on a wide set of test molecules. They were shown to be able to identify a range of highly potent AT(1) antagonists, among those a number of recently launched drugs and some candidates presently undergoing clinical tests and/or development phases. The results of our study provide confidence for the utility of the selected chemical feature based pharmacophore models to retrieve structurally diverse compounds with desired biological activity by virtual screening.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12593652     DOI: 10.1021/jm021032v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.

Authors:  Rand Shahin; Saja Alqtaishat; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2011-12-14       Impact factor: 3.686

Review 2.  Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.

Authors:  I M Kapetanovic
Journal:  Chem Biol Interact       Date:  2006-12-16       Impact factor: 5.192

3.  First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

Authors:  Puranik Purushottamachar; Aakanksha Khandelwal; Pankaj Chopra; Neha Maheshwari; Lalji K Gediya; Tadas S Vasaitis; Robert D Bruno; Omoshile O Clement; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

4.  Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.

Authors:  Jing Zhang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2009-02-11       Impact factor: 1.810

5.  Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.

Authors:  Sawsan Abuhamdah; Maha Habash; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2013-12-12       Impact factor: 3.686

6.  Discovery of new β-D-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.

Authors:  Reema Abu Khalaf; Ahmed Mutanabbi Abdula; Mohammad S Mubarak; Mutasem O Taha
Journal:  J Mol Model       Date:  2010-05-21       Impact factor: 1.810

7.  Design, Synthesis, Molecular Docking Analysis and Biological Evaluations of 4-[(Quinolin-4-yl)amino]benzamide Derivatives as Novel Anti-Influenza Virus Agents.

Authors:  Chao Zhang; Yun-Sang Tang; Chu-Ren Meng; Jing Xu; De-Liang Zhang; Jian Wang; Er-Fang Huang; Pang-Chui Shaw; Chun Hu
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

8.  Common pharmacophore identification using frequent clique detection algorithm.

Authors:  Yevgeniy Podolyan; George Karypis
Journal:  J Chem Inf Model       Date:  2009-01       Impact factor: 4.956

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.